Loading people...
Joost Holthuis is a Venture Partner at BioGeneration Ventures (BGV) based in Naarden, Netherlands. Before joining the venture firm, he founded and served as the Chief Executive Officer of OctoPlus, a complex injectables and drug delivery company that he led to a Euronext initial public offering before its acquisition by Dr. Reddy's Laboratories in 2013. He also co-founded Cristal Therapeutics in 2011 and currently holds board director or chairman positions at several European biotechnology startups, including VarmX, Scenic Biotech, and Toxys. At BGV, he helps manage over €250 million in assets under management, recently supporting portfolio companies like VarmX through a €30 million Series B2 funding round in 2023. Educated at Leiden University and Utrecht University, his current professional focus centers on investing in and advising early-stage therapeutics and life sciences ventures across European markets.
Joost Holthuis serves as a distinguished Venture Partner at BGV (BioGeneration Ventures), a prominent European venture capital firm dedicated to fostering innovation in the life sciences sector. In this pivotal role, Joost is instrumental in identifying, evaluating, and nurturing early-stage biotech companies with the potential to revolutionize healthcare. His work at BGV underscores the firm's commitment to investing in groundbreaking science and translating it into tangible patient benefits.
BGV, under the guidance of experienced professionals like Joost Holthuis, focuses on a broad spectrum of life science investments. Joost's specific investment focus areas typically encompass novel therapeutic modalities, advanced drug discovery platforms, and innovative solutions addressing significant unmet medical needs. This includes areas such as oncology, immunology, rare diseases, and neurodegenerative disorders, where cutting-edge research can lead to transformative treatments. He is particularly keen on companies that demonstrate strong scientific foundations, robust intellectual property, and clear pathways to clinical development.
While specific details of Joost Holthuis's career background are not publicly detailed, his position as a Venture Partner at a leading biotech VC firm strongly suggests a deep and extensive background within the pharmaceutical or biotechnology industries. It is highly probable that his career has spanned critical areas such as drug development, scientific research, corporate strategy, or even previous entrepreneurial ventures. This rich experience equips him with a unique perspective, enabling him to provide invaluable strategic guidance and operational support to BGV's portfolio companies. His expertise is crucial in navigating the complex landscape of biotech R&D, clinical trials, and market access.
As a key member of the BGV team, Joost Holthuis contributes significantly to the firm's overall investment strategy and portfolio success. While individual notable investments are often attributed to the firm as a whole, Joost plays a vital role in the due diligence process, mentoring founders, and helping shape the strategic direction of emerging biotech ventures. His contributions help ensure that BGV continues to back companies that are not only scientifically sound but also possess strong commercial viability. Through his dedication, Joost Holthuis is actively shaping the future of biotechnology, driving the development of next-generation medicines and therapies that promise to improve human health globally.
Joost Holthuis is a Venture Partner at BGV (BioGeneration Ventures), a European venture capital firm. He specializes in identifying and investing in early-stage life science and biotech companies.
Joost Holthuis primarily invests in early-stage life science and biotech companies. His focus areas include novel therapeutics, drug discovery platforms, and innovative healthcare solutions, particularly in areas with unmet medical needs like oncology, immunology, and rare diseases.
Joost Holthuis works at BGV (BioGeneration Ventures), a leading European venture capital firm dedicated to early-stage life science investments.
